Full Press Release Details
Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B.
BIIB
Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B
Key Takeaway: Alprolix® (rFIXFc) Approved in the EU for the Treatment of Haemophilia B
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis